Trial Profile
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Irinotecan; Temozolomide
- Indications CNS cancer; Glioma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 28 Sep 2023 Planned End Date changed from 31 Mar 2024 to 22 Sep 2024.
- 24 Apr 2023 Planned End Date changed from 7 Apr 2023 to 31 Mar 2024.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology